GLP‑1 Receptor Agonist Use in Adolescent Obesity

Efficacy in Adolescents

In a 2013 adolescent study, exenatide reduced BMI by 1.1–1.7 kg/m² (approximately 3–5 % BMI reduction) after 3–6 months of treatment. 1

GLP‑1 receptor agonists should be initiated only after a formal, intensive lifestyle‑modification program has failed to curb weight gain or improve obesity‑related comorbidities, and therapy must continue alongside the highest‑intensity lifestyle program available. 2
Only clinicians with demonstrated experience in anti‑obesity pharmacotherapy and familiarity with potential adverse reactions should prescribe GLP‑1 receptor agonists to adolescents. 2

Therapy should be stopped and the patient re‑evaluated if a ≥ 4 % reduction in BMI or BMI‑z‑score is not achieved after 12 weeks at the target dose. 2

The most common adverse events are mild‑to‑moderate nausea and vomiting. 1
The requirement for subcutaneous injection can be a barrier to adherence for some adolescents. 1

Treatment with GLP‑1 receptor agonists in adolescents improves fasting insulin concentrations. 1
Markers of insulin resistance show improvement following therapy. 1
β‑cell function is enhanced in adolescent recipients. 1

For adolescents ≥ 16 years, adult obesity medications (including GLP‑1 agonists) are appropriate when BMI ≥ 30 kg/m² or BMI ≥ 27 kg/m² with weight‑related comorbidities. 2
Off‑label use in children < 12 years is prohibited outside of clinical‑trial settings. 2
GLP‑1 receptor agonists must not be used as monotherapy; they require concurrent intensive lifestyle intervention. 2
Prescribing to overweight (but not obese) adolescents < 16 years is discouraged except within clinical trials. 2